2020-08-17T14:41:45-05:00 2019-09-30 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1400 BELLEVUE WA 98004 990 2018-10-01 910667886 PACIFIC NORTHWEST RESEARCH INSTITUTE PACI 2067261200 720 BROADWAY SEATTLE WA 98122 BILL REICHERT CFO 2067261200 2020-08-14 1 SARA ELIZABETH J HYRE P00235495 4254544919 2020-08-14 65.158.230.194 2020-08-14 09:36:05 PD P 9CA007D6FA4ECCBF5600246BD0FD47D8656BF948 FEE5B30F7169D6EE9EA0F64CA9DD9003D0FD5F35 2018 2020-09-23 17:36:50Z PACIFIC NW DIABETES RESEARCH INST JOHN WECKER 720 BROADWAY SEATTLE WA 98122 4912184 0 X WWW.PNRI.ORG X 1956 WA AN INDEPENDENT, BIOMEDICAL RESEARCH INSTITUTE AIMED AT UNDERSTANDING HOW HEALTH IS MAINTAINED IN THE FACE OF GENETIC AND ENVIRONMENTAL RISKS ASSOCIATED WITH DISEASE DEVELOPMENT. 14 14 100 59 0 0 7566626 4266327 12583 2520 1034717 162148 148453 139014 8762379 4570009 678012 251519 0 0 6419443 6016493 0 0 491584 2837383 2893704 9934838 9161716 -1172459 -4591707 20202921 15217380 1206026 798390 18996895 14418990 X PACIFIC NORTHWEST RESEARCH INSTITUTE (PNRI), A NONPROFIT CORPORATION, IS AN INDEPENDENT, BIOMEDICAL RESEARCH INSTITUTE CONDUCTING BASIC AND APPLIED RESEARCH AIMED AT UNDERSTANDING HOW HEALTH IS MAINTAINED IN THE FACE OF GENETIC AND ENVIRONMENTAL RISKS ASSOCIATED WITH DISEASE DEVELOPMENT. THE SCIENTIFIC DISCOVERIES HAVE APPLICABILITY IN A VARIETY OF DISEASES, INCLUDING DIABETES, CANCER, NEUROLOGICAL DISORDERS, AMONG MANY OTHERS. 0 0 3378822 2520 PNRI'S CLINICAL RESOURCES AND CAPABILITIES ARE AT THE CENTER OF THE PURSUIT TO TRANSLATE SCIENTIFIC DISCOVERIES INTO HEALTH IMPACT. EXAMPLES OF OUR CLINICAL DIABETES RESEARCH INCLUDES: 1) DETERMINING THE EFFICACY OF ANTIOXIDANTS IN PROTECTING BETA CELL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES; 2) IMPROVING METHODS FOR DETERMINING THE GENETIC RISK FOR TYPE 1 DIABETES IN NEWBORNS; 3) IDENTIFYING BIOMARKERS ASSOCIATED WITH EARLY ONSET OF TYPE 1 DIABETES; 4) IDENTIFYING POTENTIAL ENVIRONMENTAL TRIGGERS ASSOCIATED WITH AN INCREASED RISK OF DEVELOPING TYPE 1 DIABETES; AND 5) EVALUATING THE EFFICACY OF VARIOUS LOW-TOXICITY, IMMUNE THERAPIES IN RECENTLY DIAGNOSED TYPE 1 PATIENTS. 2534117 251519 PNRI CONTINUES TO EXPAND AND STRENGTHEN THE BIOINFORMATICS AND GENOMICS RESEARCH PLATFORM TO ENABLE THE INVESTIGATION OF THE FUNDAMENTAL CAUSES OF A VARIETY OF DISEASES, INCLUDING DIABETES. PNRI BELIEVES THAT BETTER UNDERSTANDING THE ROLE OF THE INTERACTION BETWEEN THE ENVIRONMENT AND GENETICS, AS WELL AS EPIGENETICS AND TRANSGENERATIONAL HEREDITY, WILL GENERATE INSIGHTS INTO THE PREVENTION OF HUMAN DISEASES. IN FY18, WE COMMITTED SIGNIFICANT RESOURCES TO NEW EQUIPMENT, INTELLECTUAL PROPERTY RIGHTS, FOUNDATIONAL RESEARCH, AND RECRUITMENT OF NEW SCIENTISTS. EXAMPLES OF OUR RESEARCH USING THIS PLATFORM INCLUDE: 1) APPLYING COMPUTATIONAL ANALYSIS TO IDENTIFY GENE-GENE INTERACTIONS CONTRIBUTING TO DISEASE PHENOTYPES; 2) EXPLORING THE EMERGING FIELD OF EXTRACELLULAR RNA (EXRNA) AND ITS POTENTIAL ROLE AS A COMMUNICATION MODALITY BETWEEN CELLS IN THE HUMAN BODY; 3) DETERMINING THE CONTRIBUTION OF TRANSGENERATIONAL HEREDITY IN GOVERNING BODY WEIGHT AND RISK OF METABOLIC DISEASE; AND 4) APPLYING COMPUTATIONAL AND EXPERIMENTAL METHODS IN YEAST MODEL SYSTEMS TO IDENTIFY METABOLITES ASSOCIATED WITH A VARIETY OF HUMAN DISEASES. 668725 THE APPROACHES AND METHODS DEVELOPED AS PART OF PNRI'S GENOMICS AND BIOINFORMATICS PLATFORM HAVE APPLICABILITY TO THE STUDY OF MANY DISEASES. EXAMPLES OF RESEARCH IN OTHER DISEASES INCLUDE THE IDENTIFICATION OF GENES THAT CONFER SUSCEPTIBILITY TO TESTICULAR CANCER, AND THE STUDY OF STRUCTURE AND FUNCTION OF GLYCOSPHINGOLIPIDS IN CELL COMMUNICATION AS IT RELATES TO CANCER. 457549 THE SUBSTANTIAL EXPERTISE AND LEADERSHIP OF SEVERAL OF PNRI'S SCIENTISTS IN THE FIELD OF BASIC DIABETES RESEARCH, COUPLED WITH THE URGENT NEED FOR SOLUTIONS TO THE GLOBAL EPIDEMIC, KEEP DIABETES AT THE FOREFRONT OF RESEARCH AT PNRI. EXAMPLES OF PNRI'S BASIC DIABETES RESEARCH INCLUDE: 1) IDENTIFYING MECHANISMS LEADING TO THE GRADUAL FAILURE OF BETA CELL FUNCTION OVER TIME AFTER SUCCESSFUL AUTO-ISLET CELL TRANSPLANTATION FROM THE PANCREAS TO THE LIVER; 2) EXPLORING THE ROLE AND MECHANISM OF POTASSIUM CHANNELS IN THE RELEASE OF INSULIN FROM BETA CELLS; AND 3) INVESTIGATING FUNCTIONAL CHANGES IN THE PANCREATIC ISLET CELLS IN UTERO ASSOCIATED WITH GESTATIONAL DIABETES. 457549 7039213 1 1 0 0 0 0 0 0 0 1 1 0 0 1 0 0 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 25 0 1 100 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 14 14 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 WA X BILL REICHERT 2065681468 720 BROADWAY SEATTLE WA 98122 LINDA MAUZY BOARD CHAIR 2.00 X X 0 0 0 CINDY HABA SECRETARY 2.00 X X 0 0 0 MIKE BOYLE TREASURER 2.00 X X 0 0 0 TERA EEKES TRUSTEE 1.00 X 0 0 0 CATHERINE FISHER TRUSTEE 1.00 X 0 0 0 PETER GARLOCK TRUSTEE 1.00 X 0 0 0 ALLISON HANDY TRUSTEE 1.00 X 0 0 0 TOM HAYWARD TRUSTEE 1.00 X 0 0 0 IMANTS HOLMQUIST TRUSTEE 1.00 X 0 0 0 GARY KOCHER TRUSTEE 1.00 X 0 0 0 HANS LUNDIN TRUSTEE 1.00 X 0 0 0 STEPHAN MARTINEZ TRUSTEE 1.00 X 0 0 0 JOE PIPER TRUSTEE 1.00 X 0 0 0 RON SIMS TRUSTEE 1.00 X 0 0 0 JENNIFER SIZEMORE TRUSTEE 1.00 X 0 0 0 HENRY WARDEN TRUSTEE 1.00 X 0 0 0 JOHN WECKER CEO 40.00 X 307100 0 13685 STEVE WHITE DIRECTOR OF FINANCE THRU 7/19 40.00 X 82695 0 4521 BILL REICHERT CFO FROM 7/19 40.00 X 0 0 0 JOSEPH NADEAU PRINCIPAL SCIENTIST 40.00 X 298686 0 23280 DAVID GALAS PRINCIPAL SCIENTIST 40.00 X 298426 0 15030 WILLIAM HAGOPIAN PRINCIPAL SCIENTIST 40.00 X 194639 0 25980 AIMEE DUDLEY SCIENTIST 40.00 X 141187 0 24328 RICHARD MCLAUGHLIN SCIENTIST 40.00 X 128875 0 10756 MICHAEL METZGER SCIENTIST 40.00 X 118588 0 4529 JOHN FAUVER OPERATIONS OFFICER 40.00 X 114374 0 6680 CHRISTINE BEDDIA DIRECTOR OF DEVELOPMENT 40.00 X 108647 0 0 1793217 0 128789 9 0 1 0 0 155525 3826397 284405 31540 4266327 ANALYTICAL FEES 900099 2520 2520 2520 162148 162148 418364 134765 283599 283599 283599 46040 155525 207410 -161370 -161370 13200 0 13200 13200 REBATES 900099 3585 3585 3585 4570009 2520 0 301162 247719 247719 3800 3800 1337319 872916 464403 3693879 3059240 337922 296717 52943 44778 3662 4503 553971 432384 85730 35857 378381 295984 59794 22603 66673 28050 34049 4574 106999 45016 54643 7340 490 490 721357 336635 336595 48127 135583 90630 32614 12339 33180 31984 982 214 384576 363476 17576 3524 68654 47760 16628 4266 46300 32042 12261 1997 2257 225 2009 23 369675 346994 18867 3814 35851 33651 1830 370 LAB & EQUIPMENT COSTS 615081 584131 27616 3334 BAD DEBT 87608 8734 77990 884 DUES, FEES, LICENSES 73383 43003 18487 11893 UBI TAX 12456 12456 133581 90061 14315 29205 9161716 7039213 1630919 491584 252589 101908 2261828 1563564 1098217 630755 46386 136731 120000 164672 240633 236126 13508186 9366129 4220723 4142057 7601519 4028535 57545 57546 4303481 4155486 20202921 15217380 911743 594906 284198 195510 10085 7974 1206026 798390 X 14603824 10176257 15500 0 4377571 4242733 18996895 14418990 20202921 15217380 X -4591707 161887 -148085 X 0 1 X 1 1 1 X 8540797 8822913 7618888 7566626 4266327 36815551 8540797 8822913 7618888 7566626 4266327 36815551 3650631 33164920 637840 726039 653995 563654 580512 3162040 50223 2788 3585 56596 40034187 117999 0.82840 0.84070 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2014 AMOUNT: $ 3,104. 2017 AMOUNT: $ 58. UNEMPLOYMENT REIMBURSEMENTS - 2014 AMOUNT: $ 47,119. REBATES - 2017 AMOUNT: $ 2,730. 2018 AMOUNT: $ 3,585. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 85082 -10057 75025 82406 2676 85082 76981 6412 987 82406 75000 2828 847 76981 75000 75000 0.00000 1.00000 0.00000 0 0 823359 823359 9388422 6912377 2476045 3296405 2453752 842653 4142057 PERPETUAL TRUST 4155486 4155486 ANNUITY OBLIGATION 7974 7974 4926496 161887 -147085 14802 4911694 490 -342175 -341685 4570009 9504401 343175 343175 9161226 490 490 9161716 PART V, LINE 4: THE ORGANIZATION'S ENDOWMENT FUNDS ARE DESIGNATED FOR USE AS OPERATING RESERVES AND SCIENTIST RECRUITMENT. PART XI, LINE 2D - OTHER ADJUSTMENTS: LOSS ON PERPETUAL TRUST -147,085. PART XI, LINE 4B - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSE NETTED AGAINST SPECIAL EVENT REVENUE -207,410. RENTAL EXPENSE NETTED AGAINST RENTAL REVENUE -134,765. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSE NETTED AGAINST SPECIAL EVENT REVENUE 207,410. RENTAL EXPENSE NETTED AGAINST RENTAL REVENUE 134,765. PRIOR YEAR PLEDGE WRITE-OFF 1,000. EVENING OF WINE 201565 155525 46040 76809 10061 19036 101504 201565 155525 46040 76809 10061 19036 101504 207410 -161370 1 INSTITUTE FOR SYSTEMS BIOLOGY 401 TERRY AVE N SEATTLE WA 98109 912003593 501(C)(3) 62750 N/A N/A SUB-AWARDS SEATTLE INSTITUTE FOR BIOMEDICAL AND CLINICAL RESEARCH 1325 4TH AVENUE SEATTLE WA 98101 911452438 501(C)(3) 71164 N/A N/A SUB-AWARDS PRINCETON UNIVERSITY 701 CARNEGIE CENTER PRINCETON NJ 98540 210634501 501(C)(3) 113805 N/A N/A SUB-AWARDS 3 0 PART I, LINE 2: THE ORGANIZATION HAS A FORMAL SUB CONTRACT WITH THE AGENCY AND PERFORMS ANNUAL MONITORING INCLUDING REVIEW OF THE AGENCY'S A-133 AUDIT. X X X X X 0 0 0 0 0 0 0 0 0 JOHN WECKER CEO 307100 0 0 0 0 0 8250 0 5435 0 320785 0 0 0 JOSEPH NADEAU PRINCIPAL SCIENTIST 298686 0 0 0 0 0 8250 0 15030 0 321966 0 0 0 DAVID GALAS PRINCIPAL SCIENTIST 298426 0 0 0 0 0 0 0 15030 0 313456 0 0 0 WILLIAM HAGOPIAN PRINCIPAL SCIENTIST 194639 0 0 0 0 0 5940 0 20040 0 220619 0 0 0 AIMEE DUDLEY SCIENTIST 141187 0 0 0 0 0 4288 0 20040 0 165515 0 0 0 X AUCTION ITEMS 28 31540 FAIR MARKET VALUE 0 0 1 0 PART I, COLUMN (B): THE TOTAL IN COLUMN B REPRESENTS TOTAL ITEMS CONTRIBUTED. FORM 990, PART I, LINE 6: VOLUNTEERS PROVIDE SUPPORT FOR DIABETES RESEARCH CONDUCTED IN LABS, ADMINISTRATION AND GOVERNANCE SERVICES, AND SUPPORT FOR FUNDRAISING ACTIVITIES. 16 VOLUNTEERS SERVE AS BOARD MEMBERS AT VARIOUS TIMES DURING THE YEAR. FORM 990, PART VI, SECTION B, LINE 11B THE CEO, CFO AND FINANCE COMMITTEE CHAIR WILL REVIEW THE FORM 990 PRIOR TO FILING WITH THE IRS. THE PUBLIC DISCLOSURE COPY WILL BE DISTRIBTED AND DISCUSSED AT A SUBSEQUENT BOARD MEETING. ELECTRONIC COPIES OF THE PUBLIC DISCLOSURE VERSION OF FORM 990 WILL BE DISTRIBUTED TO THE ENTIRE BOARD, AND PHYSICAL COPIES OF THE FULL FORM 990 WILL BE MADE AVAILABLE ONSITE UPON REQUEST. FORM 990, PART VI, SECTION B, LINE 12C ANNUALLY, PER INSTITUTE CONFLICT OF INTEREST POLICY THE FINANCE & AUDIT COMMITTEE SUBMITS A BOARD QUESTIONNAIRE TO ALL TRUSTEES AND KEY STAFF. ALL RESPONSES ARE GATHERED AND REVIEWED BY THE COMMITTEE CHAIR AND THE CFO. THE RESULTS ARE DISCUSSED AT THE FINANCE & AUDIT COMMITTEE MEETING. THE COMMITTEE CHAIR THEN PRESENTS THE RESULTS TO THE FULL BOARD AND ACTION IS TAKEN AS NEEDED. IF A POTENTIAL CONFLICT OF INTEREST AROSE DURING THE YEAR, THE BOARD MEMBER WOULD CONTACT OUR COMMITTEE CHAIR AND DISCLOSE THE MATTER AND BOARD REVIEW AND ACTION WOULD BE TAKEN AT THE NEXT MEETING TO ALERT ALL MEMBERS. FORM 990, PART VI, SECTION B, LINE 15 THE CEO, CFO, AND KEY EMPLOYEES HAVE THEIR INITIAL SALARY AND ANY NON-COST OF LIVING ADJUSTMENT INCREASES DOCUMENTED BY A SALARY SURVEY PROCESS CONDUCTED BY OUR INDEPENDENT HUMAN RESOURCES CONSULTING FIRM. IN ADDITION THE CEO CONTRACT IS APPROVED BY BOARD EXECUTIVE COMMITTEE. COMPENSATION REVIEWS ARE PERFORMED ANNUALLY. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9: LOSS ON PERPETUAL TRUST -147,085. PRIOR YEAR PLEDGE WRITE-OFF -1,000.